Results 131 to 140 of about 267,001 (338)

Spider venom administration impairs glioblastoma growth and modulates immune response in a non-clinical model. [PDF]

, 2020
Molecules from animal venoms are promising candidates for the development of new drugs. Previous in vitro studies have shown that the venom of the spider Phoneutria nigriventer (PnV) is a potential source of antineoplastic components with activity in ...
Barreto, Natália, Bonfanti, Amanda Pires, Brunetto, Sérgio, Caballero, Marcus, Cordeiro, Gabriel, Moura, Fernanda, Munhoz, Jaqueline, Ramos, Celso Dario, Rapôso, Catarina, Rocha-E-Silva, Thomaz, Sutti, Rafael, Thome, Rodolfo, Verinaud, Liana   +12 more
core   +1 more source

The Inflation Reduction Act and Etanercept

Arthritis &Rheumatology, EarlyView.
Charles L. Bennett, Jason B. Gibbons, Chadi Nabhan, Kenneth R. Carson, June M. McKoy, Kevin B. Knopf, Gerald Anderson   +6 more
wiley   +1 more source

Peripheral blood gene expression profiling shows prognostic significance for the course of interstitial lung disease in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective We used data from the placebo arm of the SENSCIS trial to determine the prognostic/predictive significance of peripheral blood cell (PBC) transcript modules for the course of forced vital capacity (FVC) in patients with systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) with and without mycophenolate mofetil (MMF) treatment ...
Shervin Assassi, Christopher P. Denton, Matthias Zwick, Ramona Schmid, Carina Ittrich, Tobias Litzenburger, Sudha Visvanathan   +6 more
wiley   +1 more source

Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors [PDF]

, 1969
John J. Costanzi, Charles A. Coltman, Lt Col   +2 more
openalex   +1 more source

Impact of Interleukin‐1 Blockade on the Development of Macrophage Activation Syndrome in Still's Disease: Incidence and Diagnostic Validity of the EULAR/ACR/PRINTO 2016 MAS Classification Criteria

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens, Greta Rogani, Laura Huber, Anouk Verwoerd, Dieneke Schonenberg‐Meinema, J. Merlijn van den Berg, Wineke Armbrust, G. Elizabeth Legger, Sylvia Kamphuis, Ellen J.H. Schatorjé, Esther P.A.H. Hoppenreijs, Joost F. Swart, Marc H.A. Jansen, Jorg van Loosdregt, Sebastiaan J. Vastert   +14 more
wiley   +1 more source

Amethopterin (methotrexate) in connective tissue disease-psoriasis and polyarthritis. [PDF]

, 1968
G. D. Kersley
openalex   +1 more source

Changes in Pain Sensitization after DMARD therapy are Associated with Changes in Disease Activity in Established Rheumatoid Arthritis

Arthritis &Rheumatology, Accepted Article.
Objective Abnormalities in pain regulatory mechanisms are common in patients with rheumatoid arthritis (RA). We investigated whether pain sensitization changes after treatment with a disease modifying anti‐rheumatic drug (DMARD) and explored associations between changes in pain sensitization and disease activity.
Burcu Aydemir, Andrew C. Heisler, Lutfiyya N. Muhammad, Jing Song, Alyssa Wohlfahrt, Daniel J. Clauw, Wendy Marder, Marcy B. Bolster, Clifton O. Bingham, Tuhina Neogi, Yvonne C. Lee   +10 more
wiley   +1 more source

The effect of methotrexate (amethopterin) on wound healing: an experimental study [PDF]

, 1965
James Calnan, Alan Davies
openalex   +1 more source

Detection of treatment effects by covariate-adjusted expected shortfall

, 2011
The statistical tests that are commonly used for detecting mean or median treatment effects suffer from low power when the two distribution functions differ only in the upper (or lower) tail, as in the assessment of the Total Sharp Score (TSS) under ...
He, Xuming, Hsu, Ya-Hui, Hu, Mingxiu
core   +1 more source

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

Arthritis &Rheumatology, Accepted Article.
Objective Despite availability of biologics and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit, Atul Singhal, Alan Kivitz, Edit Drescher, Yoshinori Taniguchi, Rosalía Martínez Pérez, Jaclyn Anderson, Ronilda D'Cunha, Weihan Zhao, Nicholas DeVogel, Julie Parmentier, Romy Christmann, Dilek Arikan, Howard Amital   +13 more
wiley   +1 more source